InflaRx N.V. (IFRX)

1,3600 -0,0100 (-0,73%) Alla chiusura: 04:00PM EDT

InflaRx N.V.

Winzerlaer Str. 2
Jena 07745
Germany
49 3641 508 180
https://www.inflarx.de

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 62

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Niels C. Riedemann M.D., Ph.D.	Co-Founder, CEO & Executive Director	N/D	N/D	1973
Prof. Renfeng Guo M.D.	Co-Founder, Chief Scientific Officer & Executive Director	N/D	N/D	1970
Dr. Thomas Taapken Ph.D.	Chief Financial Officer	N/D	N/D	1965
Ms. Derval O'Carroll	Senior VP and Global Head of Regulatory Affairs & Compliance	N/D	N/D	1966
Dr. Camilla Chong M.D.	Chief Medical Officer	N/D	N/D	1966
Mr. Jan Medina CFA	Head of Investor Relations & VP	N/D	N/D	N/D
Mr. Christian Schmid	VP and Head of Legal Affairs & General Counsel	N/D	N/D	N/D
Ms. Nicole Bertsch	Senior Director & Head of Human Resources	N/D	N/D	N/D
Dr. Maria Habel PH.D.	VP, Head of Preclinical R&D and QC	N/D	N/D	1982
Dr. Bruce P. Burnett Ph.D.	VP & Head of Medical Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Governance aziendale

L'ISS Governance QualityScore di InflaRx N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.